Sandbox Captopril tablet2
For information about , click ].

# Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider.  WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery.  The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements.  WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

# Overview
Sandbox Captopril tablet2 is {{{aOrAn}}} {{{drugClass}}} drug that is FDA approved for the treatment of {{{indication}}}.   Adverse reactions include {{{adverseReactions}}}.

## Off-Label Use and Dosage (Adult)

# Pediatric Indications and Dosage

## FDA-Labeled Indications and Dosage (Pediatric)
Condition 1
- Dosing Information

### Guideline-Supported Use
Condition 1
- Developed by: (Organization)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)====NonGuideline-Supported Use====
Condition 1
- Dosing Information
- There is limited information about Off-Label NonGuideline-Supported Use of Sandbox Captopril tablet2 in pediatric patients.

# Contraindications
- Condition 1
- Condition 2
- Condition 3
- Condition 4
- Condition 5

# Warnings
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue captopril as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mothers and fetus.
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue, captopril unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to captopril for hypotension, oliguria, and hyperkalemia.
When captopril was given to rabbits at doses about 0.8 to 70 times (on a mg/kg basis) the maximum recommended human dose, low incidences of craniofacial malformations were seen. No teratogenic effects of captopril were seen in studies of pregnant rats and hamsters. On a mg/kg basis, the doses used were up to 150 times (in hamsters) and 625 times (in rats) the maximum recommended human dose.

# Adverse Reactions

## Clinical Trials Experience

## Postmarketing Experience
(Description)

# Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
(Description)
(Description)
(Description)
(Description)
(Description)

# Use in Specific Populations

### Pregnancy
(Description)
(Description)

### Labor and Delivery
(Description)

### Nursing Mothers
(Description)

### Pediatric Use
(Description)

### Geriatic Use
(Description)

### Gender
(Description)

### Race
(Description)

### Renal Impairment
(Description)

### Hepatic Impairment
(Description)

### Females of Reproductive Potential and Males
(Description)

### Immunocompromised Patients
(Description)